Tolvaptan in patients with autosomal dominant polycystic kidney disease. Commentary on: NEJM 2012,Torres:Tolvaptan in patients with autosomal dominant polycystic kidney disease

Abstract

Poycystic kidney disease - autosomal dominant type (ADPKD) is is the most often heriditary disease of the kidney and the fourth cause of the renal failure in adults. To the clinic demonstration belongs arterial hypertension nephrolitiasis,infection

Keywords

• Tolvaptan
• patients, autosomal polycystic kidney disease
• renal function
• liver tests
• infection
• placebo